#Radiologik dj for windows x64 keygen#
Through these pathways, KRAS modifies cell transformation and inhibits the tumor suppressor pathways. KRAS is an oncogene that forms an EGFR signaling cascade through various pathways including Ras-Raf-MARK ( 10). Anti-EGFR monoclonal antibodies are therapeutic agents that can prolong survival in patients who have not responded to conventional treatments ( 9). Representative among these treatments are anti-epidermal growth factor receptor (EGFR) antibody therapy and oncogenic Kirsten-ras (KRAS) mutation ( 5- 8). There have been many studies on targeted treatments and the factors that can predict response to them ( 4- 8). CRC has well-known genetic mechanisms ( 2, 3) that are exploited clinically for individualized patient treatments. Accepted for publication Dec 19, 2018.Ĭolorectal cancer (CRC) is associated with a variety of environmental, genetic and epigenetic factors and arises due to a combination of these factors ( 1). Keywords: Magnetic resonance imaging (MRI) apparent diffusion coefficient (ADC) Kirsten-ras (KRAS) mutation rectal neoplasms relative contrast enhancement However, it showed a low accuracy of 64% for prediction of KRAS mutation.
The other qualitative findings also did not show any significant difference (P>0.05).Ĭonclusions: The ratio of axial to LTL showed a significant difference according to KRAS mutation in patients with primary rectal cancer. The relative contrast enhancement showed no significant difference between the two groups (1.66☐.93, 1.35☐.84, P=0.1581). The mean ADC of the mutant group was not significantly different from that of the wild-type group. Results: The ratio of axial to LTL in the KRAS-mutant group (n=41) was higher than that in the wild-type group (n=34) (0.29☐.15 0.22☐.08, P=0.0117). Molecular-biologic results served as the reference standard. An area under receiver operating characteristic curve (AUC) was considered as the diagnostic performance for the prediction of KRAS mutation. The associations among the qualitative data (tumor stage, node stage, lymphatic invasion, venous invasion, and perineural invasion), quantitative data (tumor length, ADC, relative contrast enhancement) and KRAS mutations were statistically analyzed by Fisher’s exact test for the qualitative data and by the Mann-Whitney U test for the quantitative data. Two radiologists reviewed the MRI scans and measured the axial and longitudinal tumor lengths (LTLs), apparent diffusion coefficient (ADC), and relative contrast enhancement. The rectal MRI consisted of T2-weighted images in three planes, pre- and post-contrast-enhanced T1-weighted images, and axial diffusion-weighted images (b factors, 0, 1,000 s/mm 2). Methods: Seventy-five patients with primary rectal cancer who had undergone rectal magnetic resonance imaging (MRI) were included. Background: To evaluate the association between various radiologic-pathologic findings and oncogenic Kirsten-ras (KRAS) mutation in patients with primary rectal cancer.
0 kommentar(er)
